跳至主要内容
临床试验/NCT05133752
NCT05133752已完成4 期

A Multi-Center, Open-Label, Single-Arm, Phase IV Study to Evaluate the Safety and Clinical Efficacy of Oral Administration With Nemonoxacin in Treating Elderly Patients With Community-Acquired Pneumonia

TaiGen Biotechnology Co., Ltd.1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2018年9月11日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
100
试验地点
1
主要终点
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 after treatment with oral nemonoxacin once daily for 7-10 days

研究概览

简要总结

This study was to evaluate the safety and efficacy of oral nemonoxacin in treating elderly patients (aged ≥ 65 years) with community-acquired pneumonia (CAP).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥65 years
  • Clinical diagnosis of CAP
  • Evidence of inflammatory exudates or infiltrates on chest X-ray

排除标准

  • Suspect viral pneumonia, aspiration pneumonia, ventilator-associated pneumonia or hospital-acquired pneumonia
  • History of hypersensitivity to quinolone or fluoroquinolone

研究组 & 干预措施

Nemonoxacin

Experimental

干预措施: Nemonoxacin (Drug)

结局指标

主要结局

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 after treatment with oral nemonoxacin once daily for 7-10 days

时间窗: From Visit 1 (Baseline) till Visit 3 (within 24 hr after last dose)

次要结局

  • Number of participants with clinical success in the modified intention-to-treat (mITT) population, intention-to-treat (ITT), and clinically evaluable (CE) populations.(Visit 3 (within 24 hr after last dose))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验